Get the Stockscreener App
20.17
1.27%
-0.26
Rigel Pharmaceuticals stock is traded at $20.17, with a volume of 164.01K.
It is down -1.27% in the last 24 hours and up +8.27% over the past month.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
See More
Previous Close:
$20.43
Open:
$20.54
24h Volume:
164.01K
Relative Volume:
0.84
Market Cap:
$360.49M
Revenue:
$116.88M
Net Income/Loss:
$-25.09M
P/E Ratio:
-144.07
EPS:
-0.14
Net Cash Flow:
$-20.74M
1W Performance:
+7.29%
1M Performance:
+8.27%
6M Performance:
-9.02%
1Y Performance:
+85.05%
1-Day Range:
$20.00
$20.64
1-Week Range:
$18.80
$21.38
52-Week Range:
$8.61
$29.82
Rigel Pharmaceuticals Stock (RIGL) Company Profile
Name
Rigel Pharmaceuticals
Sector
Industry
Phone
650-624-1100
Address
611 GATEWAY BOULEVARD, SUITE 900, SOUTH SAN FRANCISCO, CA
Compare RIGL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RIGL
Rigel Pharmaceuticals
|
20.17 | 365.13M | 116.88M | -25.09M | -20.74M | -0.14 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.47 | 32.08B | 3.81B | -644.79M | -669.77M | -6.24 |
Rigel Pharmaceuticals Stock (RIGL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-03-23 | Resumed | Piper Sandler | Neutral |
| Jun-09-22 | Downgrade | Citigroup | Buy → Neutral |
| Jun-08-22 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jun-08-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Mar-23-22 | Initiated | B. Riley Securities | Neutral |
| Nov-09-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-15-19 | Resumed | Cantor Fitzgerald | Overweight |
| Sep-26-19 | Resumed | JP Morgan | Overweight |
| Mar-01-19 | Reiterated | Cantor Fitzgerald | Overweight |
| Aug-27-18 | Initiated | Citigroup | Buy |
| May-02-18 | Reiterated | Cantor Fitzgerald | Overweight |
| Dec-21-17 | Resumed | Piper Jaffray | Overweight |
| Dec-15-17 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-06-17 | Resumed | H.C. Wainwright | Buy |
| Mar-09-17 | Reiterated | H.C. Wainwright | Buy |
| Aug-31-16 | Reiterated | H.C. Wainwright | Buy |
| Aug-30-16 | Reiterated | Piper Jaffray | Overweight |
| Jul-13-16 | Initiated | H.C. Wainwright | Buy |
| Jun-13-16 | Initiated | Piper Jaffray | Overweight |
| Apr-22-16 | Upgrade | JP Morgan | Neutral → Overweight |
| Apr-08-13 | Reiterated | Stifel | Buy |
| Nov-29-12 | Initiated | UBS | Neutral |
| Nov-06-12 | Reiterated | Oppenheimer | Outperform |
| Mar-26-12 | Initiated | Canaccord Genuity | Hold |
| Dec-10-10 | Downgrade | MP Advisors | Outperform → Market Perform |
View All
Rigel Pharmaceuticals Stock (RIGL) Latest News
Eli Lilly and Rigel Pharmaceuticals: Promising Advances in Rheumatoid Arthritis Treatment - TipRanks
Will Rigel Pharmaceuticals Inc. stock benefit from AI tech trendsHigh-impact stock picks - jammulinksnews.com
Is Rigel Pharmaceuticals Inc. a good long term investmentAccelerated wealth building - PrintWeekIndia
What institutions are buying Rigel Pharmaceuticals Inc. stock nowHigh-margin investment plays - jammulinksnews.com
What analysts say about Rigel Pharmaceuticals Inc. stockStrongest growth potential - PrintWeekIndia
What drives Rigel Pharmaceuticals Inc. stock priceHigh-margin investment plays - Autocar Professional
Institutional investors have a lot riding on Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) with 65% ownership - simplywall.st
Eli Lilly and Rigel Pharmaceuticals Advance Rheumatoid Arthritis Study with LY3871801 - TipRanks
Rigel Pharmaceuticals Inc. Stock Analysis and ForecastFastest-growing stock picks - jammulinksnews.com
(RIGL) Proactive Strategies - news.stocktradersdaily.com
What makes Rigel Pharmaceuticals Inc. stock price move sharplyHigh Potential Stock Ideas - newser.com
Why Rigel Pharmaceuticals Inc. stock attracts strong analyst attentionFree Top-Rated Stock Analysis - Newser
H.C. Wainwright Reiterates a Buy Rating on Rigel Pharmaceuticals (RIGL) - Insider Monkey
(RIGL) Long Term Investment Analysis - news.stocktradersdaily.com
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) | RIGL Stock News - GuruFocus
Rigel Pharmaceuticals, Inc. Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - 富途牛牛
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NA - GuruFocus
Recent 11% pullback isn't enough to hurt long-term Rigel Pharmaceuticals (NASDAQ:RIGL) shareholders, they're still up 112% over 1 year - simplywall.st
Rigel Pharmaceuticals’ SWOT analysis: promising pipeline drives stock potential By Investing.com - Investing.com Canada
Rigel Pharmaceuticals’ SWOT analysis: promising pipeline drives stock potential - Investing.com
High-grade Glioma Market Expected to Experience Major Growth by 2034, According to DelveInsight | Rigel Pharma, Orbus Therapeutics, BioMimetix, Bayer, MedImmune, DNAtrix, Chimerix, CNS Pharma - Barchart.com
Wellington Management Group LLP Makes New Investment in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) - Defense World
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Shares Sold by Nuveen Asset Management LLC - Defense World
Two Sigma Investments LP Makes New $1.03 Million Investment in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) - Defense World
Rigel Pharmaceuticals at Jefferies Conference: Strategic Growth and Innovation By Investing.com - Investing.com Nigeria
Millennium Management LLC Takes $1.19 Million Position in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) - Defense World
Rigel Pharmaceuticals at Jefferies Conference: Strategic Growth and Innovation - Investing.com
Rigel Pharma To Present At Jefferies Global Healthcare Conference; Webcast At 12:50 PM ET - Nasdaq
Deutsche Bank AG Increases Holdings in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) - Defense World
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Receives Average Rating of “Hold” from Brokerages - Defense World
Is Rigel Pharmaceuticals (RIGL) Stock Undervalued Right Now? - Yahoo Finance
Rigel to Present at the Jefferies Global Healthcare Conference - StreetInsider
Director Lapointe Anthony Gregg was granted 2,500 shares, increasing direct ownership by 25% to 12,500 units (SEC Form 4) - Quantisnow
Director Hannah Alison L. was granted 2,500 shares, increasing direct ownership by 31% to 10,625 units (SEC Form 4) - Quantisnow
Rigel Pharmaceuticals Stock (RIGL) Financials Data
Revenue
Net Income
Cash Flow
EPS
Rigel Pharmaceuticals Stock (RIGL) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Schorno Dean L | EVP & Chief Financial Officer |
Feb 05 '25 |
Sale |
21.93 |
1,734 |
38,020 |
57,235 |
| Santos David A | EVP, Chief Commercial Officer |
Feb 04 '25 |
Sale |
20.92 |
2,125 |
44,457 |
53,500 |
| Santos David A | EVP, Chief Commercial Officer |
Feb 05 '25 |
Sale |
21.93 |
1,796 |
39,379 |
51,704 |
| RODRIGUEZ RAUL R | CEO, President |
Feb 04 '25 |
Sale |
20.92 |
4,952 |
103,601 |
243,854 |
| RODRIGUEZ RAUL R | CEO, President |
Feb 05 '25 |
Sale |
21.93 |
4,400 |
96,474 |
239,454 |
| Furey Raymond J. | EVP, GC, CCO & Corp Sec |
Feb 04 '25 |
Sale |
20.92 |
1,448 |
30,294 |
40,169 |
| Furey Raymond J. | EVP, GC, CCO & Corp Sec |
Feb 05 '25 |
Sale |
21.93 |
1,339 |
29,359 |
38,830 |
0.97%
0.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):